Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness
Autor: | Tsai-Teng Tzeng, Lily Hui-Ching Wang, Alan Yung-Chih Hu, Min-Shi Lee, Po-Ling Chen |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
viruses Immunology lcsh:Medicine Biology Vero cell-derived influenza vaccine medicine.disease_cause Virus Article 03 medical and health sciences 0302 clinical medicine Antigen Drug Discovery Pandemic medicine Pharmacology (medical) 030212 general & internal medicine Pharmacology lcsh:R Embryonated virus diseases Virology Influenza A virus subtype H5N1 master donor virus 030104 developmental biology Infectious Diseases Immunization Preparedness Vero cell pandemic preparedness |
Zdroj: | Vaccines, Vol 8, Iss 626, p 626 (2020) Vaccines Volume 8 Issue 4 |
Popis: | The embryonated egg-based platform currently produces the majority of seasonal influenza vaccines by employing a well-developed master donor virus (MDV, A/PR/8/34 (PR8)) to generate high-growth reassortants (HGRs) for A/H1N1 and A/H3N2 subtypes. Although the egg-based platform can supply enough seasonal influenza vaccines, it cannot meet surging demands during influenza pandemics. Therefore, multi-purpose platforms are desirable for pandemic preparedness. The Vero cell-based production platform is widely used for human vaccines and could be a potential multi-purpose platform for pandemic influenza vaccines. However, many wild-type and egg-derived influenza viruses cannot grow efficiently in Vero cells. Therefore, it is critical to develop Vero cell-derived high-growth MDVs for pandemic preparedness. In this study, we evaluated two in-house MDVs (Vero-15 and VB5) and two external MDVs (PR8 and PR8-HY) to generate Vero cell-derived HGRs for five avian influenza viruses (AIVs) with pandemic potentials (H5N1 clade 2.3.4, H5N1 clade 2.3.2.1, American-lineage H5N2, H7N9 first wave and H7N9 fifth wave). Overall, no single MDV could generate HGRs for all five AIVs, but this goal could be achieved by employing two in-house MDVs (vB5 and Vero-15). In immunization studies, mice received two doses of Vero cell-derived inactivated H5N1 and H7N9 whole virus antigens adjuvanted with alum and developed robust antibody responses. |
Databáze: | OpenAIRE |
Externí odkaz: |